46P - Novel role of apatinib as a multi-target RTK inhibitor in the direct suppression of hepatocellular carcinoma cells

Date 11 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Cancer biology
Hepatobiliary Cancers
Basic Scientific Principles
Presenter Xiaojin Li
Citation Annals of Oncology (2017) 28 (suppl_5): v1-v21. 10.1093/annonc/mdx361
Authors X. Li1, A. Xu1, H. Li2, B. Zhang1, B. Cao2, J. Huang1
  • 1Experimental Center;national Clinical Research Center For Digestive Disease, Beijing Friendship Hospital, Capital Medical University, 100050 - Beijing/CN
  • 2Department Of Oncology, Beijing Friendship Hospital, Capital Medical University, 100050 - Beijing/CN



Although apatinib has been demonstrated with potential antitumor activity to multiple solid tumors, the underlying mechanism of apatinib for the treatment of hepatocellular carcinoma (HCC) remains unclear. In the present study, we explore if there is any direct suppression effect of apatinib on HCC cells and its relevant targets.


To determine the role of apatinib, we investigated its effect on viability, colony formation, apoptosis, migration of 6 HCC cell lines in vitro, and HCC progression in mice model. Using a phospho-receptor tyrosine kinase pathway array with 49 different tyrosine kinases, we screened and verified the tyrosine kinase targets involved in apatinib therapy.


Apatinib treatment significantly inhibited HCC cell viability, proliferation, colony formation, migration, and enhanced cell apoptosis in a concentration-dependent manner (p


These novel data suggested that the apatinib may have a direct anti-HCC effects as a direct multi-target RTK inhibitor of HCC cells and a promising potentiality in HCC clinical therapies.

Clinical trial identification

Legal entity responsible for the study

Xiaojin Li




All authors have declared no conflicts of interest.